WAVE LIFE SCIENCES LTD. Debt Conversion, Converted Instrument, Amount
WAVE LIFE SCIENCES LTD. (WVE) reported Debt Conversion, Converted Instrument, Amount of $9.60 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2018-03-12
- WAVE LIFE SCIENCES LTD. debt conversion, converted instrument, amount for the quarter ending 2014-12-31 was $0.00.
- WAVE LIFE SCIENCES LTD. debt conversion, converted instrument, amount for fiscal 2014 was $9.60M.
| Period end | Debt Conversion, Converted Instrument, Amount 1 month | Debt Conversion, Converted Instrument, Amount 1 month as first filed | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $9.60M 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $9.60M 10-Q · filed 2015-12-17 | ||||
| 2014-02-28 | $9.60M 10-K · filed 2018-03-12 | $9.60M 10-Q · filed 2015-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |